KIKeiji Iwatsuki

Keiji Iwatsuki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Keiji Iwatsuki has a total of 278 co-authors. Here are the top co-authors by number of shared publications:

  • Shin Morizane

    Department of Dermatology Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences Okayama Japan

    18 shared publications
  • Osamu Yamasaki

    Department of Dermatology Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Okayama Japan

    16 shared publications
  • Takenobu Yamamoto

    14 shared publications
  • Tomoko Miyake

    Department of Dermatology Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences Okayama Japan

    14 shared publications
  • Kenji Asagoe

    Department of Dermatology National Hospital Organization Okayama Medical Center

    13 shared publications
  • Yoji Hirai

    Department of Dermatology Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences Okayama Japan

    12 shared publications

Latest Publications

  • Open Access

    Diagnostic and disease severity determination criteria for hydroa vacciniforme lymphoproliferative disorders and severe mosquito bite allergy

    by Yoji Hirai, Hideo Asada, Toshihisa Hamada, Jun‐Ichi Kawada, Hiroshi Kimura, Ayako Arai, Koichi Ohshima, Shouichi Ohga, Keiji Iwatsuki, Committee for Guidelines for the Management of Chronic Active EBV Disease and Related Disorders (the MHLW Research Team in Japan)

    Hydroa vacciniforme lymphoproliferative disorder (HV‐LPD) and severe mosquito bite allergy (SMBA) are both cutaneous forms of Epstein–Barr virus (EBV)‐associated T/natural killer (NK) cell LPDs and are closely related to chronic active EBV disease (CAEBV) and EBV‐associated hemophagocytic lymphohistiocytosis (EBV‐HLH). HV‐LPD is further divided into classic HV, a benign subtype mediated by EBV‐positive γδT cells, and systemic HV, another life‐threatening subtype mainly associated with EBV‐positive αβT or γδT cells. The vast majority of patients with SMBA have increased numbers of EBV‐infected NK cells in the blood. Clinical symptoms of HV‐LPD and SMBA often overlap in the same patient and may progress to more serious disease conditions equivalent to the systemic form of CAEBV. To define the disease spectrum of HV‐LPD and SMBA, we propose the diagnostic criteria and the determination criteria for disease severity. The proposed diagnostic criteria are consistent with those for CAEBV and EBV‐HLH in the guidelines for the management for CAEBV and related disorders 2023.


  • Open Access

    Coexpression of natural killer cell antigens by T-cell large granular lymphocytes in hydroa vacciniforme lymphoproliferative disorder and the involvement of Vδ1 + epithelial-type γδT cells

    by Yoji Hirai, Keiji Iwatsuki, Takahide Takahashi, Tomoko Miyake, Yuki Nakagawa, Shogo Tanimoto, Yoshio Kawakami, Shin Morizane

    Hydroa vacciniforme lymphoproliferative disorder (HV-LPD) is a cutaneous variant of chronic active Epstein–Barr virus disease. We examined the coexpression of T- and natural killer (NK)-cell antigens in five patients with classic HV (cHV) and five with systemic HV (sHV). T-cell receptor (TCR) repertoire analysis was performed with high‑throughput sequencing. All five cHV patients had increased γδT cells (> 5%), whereas five sHV patients showed γδT- and αβT-cell dominance in two patients each, and a mixture of abnormal γδT and αβT cells in one. Circulating CD3 + T cells expressed CD16/CD56 at 7.8–42.3% and 1.1–9.7% in sHV and cHV, respectively. The percentage of CD16/CD56 + T cells was higher in the large granular lymphocyte or atypical T-cell fractions in sHV, but no TCR Vα24 invariant chain characteristic of NKT cells was detected. Considerable numbers of CD3 + cells expressing CD56 were observed in sHV skin infiltrates. Of the circulating γδT cells tested, TCR Vδ1 + cells characteristic of the epithelial type of γδT cells were dominant in two sHV cases. Thus, atypical αβT and γδT cells in HV-LPD can express NK-cell antigens, such as CD16 and CD56, and Vδ1 + epithelial-type γδT cells are a major cell type in some HV-LPD cases.


  • Open Access

    Rituximab therapy for intractable pemphigus: A multicenter, open‐label, single‐arm, prospective study of 20 Japanese patients

    by Jun Yamagami, Yuichi Kurihara, Takeru Funakoshi, Yasuko Saito, Ryo Tanaka, Hayato Takahashi, Hideyuki Ujiie, Hiroaki Iwata, Yoji Hirai, Keiji Iwatsuki, et al.

    This was a multicenter clinical trial of rituximab, a chimeric monoclonal IgG antibody directed against CD20, for the treatment of refractory pemphigus vulgaris and pemphigus foliaceus. In total, 20 patients were treated with two doses of rituximab (1000 mg; 2 weeks apart) on days 0 and 14. The primary end point was the proportion of patients who achieved complete or partial remission on day 168 following the first rituximab dose. Of the 20 enrolled patients, 11 (55%) and four (20%) achieved complete and partial remission, respectively; therefore, remission was achieved in a total of 15 patients (75.0% [95% confidence interval, 50.9%–91.3%]). It was demonstrated that the remission rate was greater than the prespecified threshold (5%). In addition, a significant improvement in clinical score (Pemphigus Disease Area Index) and decrease in serum anti‐desmoglein antibody level were observed over time. Four serious adverse events (heart failure, pneumonia, radial fracture, and osteonecrosis) were recorded in two patients, of which only pneumonia was considered causally related with rituximab. The level of peripheral blood CD19‐positive B lymphocytes was decreased on day 28 after rituximab treatment and remained low throughout the study period until day 168. Our results confirm the efficacy and safety of rituximab therapy for refractory pemphigus in Japanese patients.


  • Analysis of clonality in cutaneous B‐cell lymphoma and B‐cell pseudolymphoma using skin flow cytometry: Comparison of immunophenotyping and gene rearrangement studies

    by Yuki Nakagawa, Toshihisa Hamada, Takahide Takahashi, Tomoko Miyake, Yoji Hirai, Keiji Iwatsuki, Shin Morizane¹

    To identify clonal neoplastic cells in skin affected by B-cell lymphoma using skin flow cytometry (FCM) techniques, we investigated light-chain restriction using skin FCM with clonality assessed by polymerase chain reaction and light-chain restriction by in situ hybridization (ISH). We retrospectively analyzed 16 cases of B-cell lymphoma with cutaneous involvement: primary cutaneous diffuse large B-cell lymphoma, leg type (pcDLBCL-LT) (n = 7), DLBCL–not otherwise specified (DLBCL-NOS) (n = 6), primary cutaneous follicle center lymphoma (pcFCL) (n = 1), and follicular lymphoma (n = 2), as well as cutaneous B-cell pseudolymphoma (n = 9). Results of skin FCM light-chain restriction analyses were compared with immunoglobulin H (IgH) gene rearrangement and κ/λ ISH findings. Skin FCM detected light-chain restriction in 11 of 14 B-cell lymphoma patients but none of the B-cell pseudolymphoma patients. The sensitivity of skin FCM for distinguishing B-cell lymphoma and B-cell pseudolymphoma was 79%, and the specificity was 100%. Eleven of 13 B-cell lymphoma patients exhibited gene rearrangement (sensitivity 85%), whereas six of seven pseudolymphoma patients were negative (specificity 86%). ISH was positive in three of 16 B-cell lymphoma cases (sensitivity 19%) but none of the B-cell pseudolymphoma cases (specificity 100%). ISH sensitivity was 29% for pcDLBCL-LT, 17% for DLBCL-NOS, and 0% for pcFCL and follicular lymphoma. Skin FCM therefore appears to be more sensitive than ISH in detecting light-chain restriction in DLBCL and follicular lymphoma, and as sensitive as IgH gene rearrangement analysis in detecting clonality. Skin FCM is thus a promising diagnostic tool for identifying monoclonal neoplastic B-cell populations.


  • Open Access

    Improved quality of life of patients with generalized pustular psoriasis in Japan: A cross‐sectional survey

    by Koremasa Hayama, Hideki Fujita, Keiji Iwatsuki, Tadashi Terui

    Generalized pustular psoriasis (GPP) is a rare variant of psoriasis with severe clinical symptoms. However, the quality of life (QoL) of the patients is largely unknown. We conducted a nationwide cross‐sectional survey of Japanese GPP patients using the 36‐Item Short‐Form Health Survey version 2 (SF‐36v2) to elucidate patients’ QoL and how their QoL had changed over the last decade. We analyzed QoL data of 83 patients obtained from 2016 to 2019 (present group) and compared it with that of 105 patients collected in a previous survey conducted between 2003 and 2007 (past group). Although the QoL of the present patients was still largely impaired in comparison with the standard Japanese population, substantial improvement was found in some SF‐36v2 subscales including “general health”, “vitality”, “social functioning” and “mental health” as compared with that of the past group. Advances in treatment may contribute to this QoL improvement.


  • Japanese guidelines for the management of pemphigoid (including epidermolysis bullosa acquisita)

    by Hideyuki Ujiie, Hiroaki Iwata, Jun Yamagami, Takekuni Nakama, Yumi Aoyama, Shigaku Ikeda, Norito Ishii, Keiji Iwatsuki, Michiko Kurosawa, Daisuke Sawamura, et al.

    The pemphigoid group is a category of autoimmune subepidermal blistering diseases in which autoantibodies deposit linearly at the epidermal basement membrane zone (BMZ). The main subtypes of pemphigoid mediated by immunoglobulin G autoantibodies are bullous pemphigoid (BP), mucous membrane pemphigoid (MMP) and epidermolysis bullosa acquisita (EBA). To establish the first guidelines approved by the Japanese Dermatological Association for the management of pemphigoid diseases, the Committee for Guidelines for the Management of Pemphigoid Diseases (Including EBA) was founded as part of the Study Group for Rare Intractable Skin Diseases under the Ministry of Health, Labor and Welfare Research Project on Overcoming Intractable Diseases. These guidelines aim to provide current information for the management of BP, MMP and EBA in Japan. Based on evidence, the guidelines summarize the clinical and immunological manifestations, pathophysiologies, diagnostic criteria, disease severity determination criteria, treatment algorithms and treatment recommendations. Because of the rarity of these diseases, there are few clinical studies with a high degree of evidence, so several parts of these guidelines were established based on the opinions of the Committee. To further optimize these guidelines, periodic revision in line with the new evidence is necessary.


  • The expression of cell adhesion molecule 1 and its splicing variants in Sézary cells and cell lines from cutaneous T‐cell lymphoma

    by Mari Yamaguchi, Shin Morizane, Toshihisa Hamada, Tomoko Miyake, Makoto Sugaya, Hiroaki Iwata, Kazuyasu Fujii, Rie Haramoto‐Shiratsuki, Yuki Nakagawa, Mayumi Miura, et al.

    Cell adhesion molecule 1 (CADM1) is aberrantly expressed by T‐cell neoplasms such as adult T‐cell leukemia/lymphoma (ATLL) and mycosis fungoides (MF). We studied the expression of CADM1 and its splicing variants in Sézary syndrome (SS), MF, other cutaneous T‐cell lymphoma (CTCL), and cell lines derived from T‐ and B‐cell lymphomas. Soluble CADM1 was measured in the patients’ sera. CADM1+ cells in the blood and skin lesions were examined by flow cytometry and immunostaining, respectively. Soluble CADM1 was measured by ELISA, and the splicing variants of CADM1 transcripts were determined by reverse transcriptase‐polymerase chain reaction, followed by sequencing. As a result, circulating CADM1+ cells were significantly increased in seven out of 10 patients with SS, ranging from 7.9% to 74.5% of the CD3+CD4+ fractions (median 33.7%; cut‐off value 6.5%). The percentages of CADM1+ cells were usually less than those of circulating Sézary cells. CADM1 was expressed, to various degrees, in six of nine T‐cell lines derived from SS, MF, ATLL, and anaplastic large cell lymphoma (ALCL), but negative in B‐cell lymphoma‐derived cell lines. CADM1+ cells were present in the skin infiltrates of MF, SS, ATLL and ALCL. Serum levels of soluble CADM1 were not significantly elevated in SS/MF. Three major splicing variants of CADM1 expressed by neoplastic T‐cells contained different combinations of the exons 7, 8, 9 and 11, including a putative oncogenic variant composed of exons 7‐8‐9‐11. In conclusion, CADM1 is frequently expressed in Sézary cells and cell lines from CTCL.


  • Clinical manifestations of skin, lung and muscle diseases in dermatomyositis positive for anti‐aminoacyl tRNA synthetase antibodies

    by Hiroko Fukamatsu, Yoji Hirai, Tomoko Miyake, Tatsuya Kaji, Shin Morizane, Emi Yokoyama, Toshihisa Hamada, Takashi Oono, Yoshinobu Koyama, Seiichiro Norikane, et al.

    Patients with dermatomyositis positive for anti‐aminoacyl tRNA synthetase (ARS) antibodies, also known as antisynthetase syndrome (ASS), frequently present with mechanic's hand and interstitial lung disease (ILD). We first screened the antibody profiles of 59 patients with dermatomyositis, and then examined the cutaneous, muscular and pulmonary manifestations characteristic for patients with ASS. The anti‐ARS antibodies Jo‐1, PL‐7, PL‐12, EJ and KS, along with antibodies to TIF1‐γ, MDA5 and Mi‐2, were examined. Among the 59 patients, 20, 21, 15 and three patients were classified into the ASS, non‐ASS, myositis‐specific antibody‐negative and unknown groups, respectively. Five of 16 patients (31%) with ASS had six relatives with a history of collagen diseases, within the second degree of relationship, including two cases of dermatomyositis (vs the non‐ASS group, P = 0.018). Patients with ASS more frequently presented with fever and arthralgia, and had elevated levels of C‐reactive protein. Nine of the 11 finger lesions (82%) clinically diagnosed as mechanic's hands showed a psoriasiform tissue reaction. ILD was observed in 19 of 20 patients (95%) with ASS, and eight of 21 patients (38%) in the non‐ASS group, in which six patients possessed anti‐MDA5 antibody. Patients with ASS showed higher serum levels of muscle enzymes, and four of 12 patients (33%) had fasciitis‐dominant myopathy, while only one of 11 patients (9%) in the non‐ASS group had fasciitis‐dominant myopathy. Patients with ASS often present with a psoriasiform tissue reaction in the hand lesions and fasciitis‐dominant myopathy, and the relatives of those with ASS are at high risk for collagen diseases.